-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, ECeTe+9Q92PjBzl0CVXAucDtM9iWNHrzdpPXF7IbMLvCD/dgCvDmnOOg2uGbXKJV vCx8VaUwlw0LD7UzBsKwJg== 0000950144-09-000114.txt : 20090108 0000950144-09-000114.hdr.sgml : 20090108 20090107212908 ACCESSION NUMBER: 0000950144-09-000114 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20090105 ITEM INFORMATION: Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers FILED AS OF DATE: 20090108 DATE AS OF CHANGE: 20090107 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MEDASSETS INC CENTRAL INDEX KEY: 0001254419 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-PREPACKAGED SOFTWARE [7372] IRS NUMBER: 510391128 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-33881 FILM NUMBER: 09514354 BUSINESS ADDRESS: STREET 1: 100 NORTH POINT CENTER EAST STREET 2: SUITE 200 CITY: ALPHARETTA STATE: GA ZIP: 30022 BUSINESS PHONE: 6783232500 MAIL ADDRESS: STREET 1: 100 NORTH POINT CENTER EAST STREET 2: SUITE 200 CITY: ALPHARETTA STATE: GA ZIP: 30022 8-K 1 g17246e8vk.htm MEDASSETS INC. MEDASSETS INC.
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): January 5, 2009
MedAssets, Inc.
 
(Exact name of registrant as specified in its charter)
         
Delaware   001-33881   51-0391128
         
(State or other jurisdiction
of incorporation) 		  (Commission
File Number) 		  (I.R.S. Employer
Identification No.)
     
100 North Point Center E, Suite 200,
Alpharetta, Georgia 		 
30022
     
(Address of principal executive
offices) 		  (Zip Code)
Registrant’s telephone number, including area code: 678-323-2500
Not Applicable
 
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o     Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 

 

 

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On January 5, 2009, the Compensation Committee of the Board of Directors of MedAssets, Inc. (the “Company”) granted equity awards totaling 3.6 million underlying shares to certain employees at a fair value of $14.74 per share, of which approximately 36% of the total grant was allocated to the Company’s named executive officers (or “NEOs”), under the Company’s new Long-Term Performance Incentive Plan (LTPIP). The table below provides more specific information regarding the grants to the NEOs.
The Compensation Committee also resolved that Cash Earnings per Share growth, or Cash EPS growth, will be used as the criteria for the awards of stock-settled stock appreciation rights (SSARs) and restricted stock subject to vesting based on the Company’s financial performance. Cash EPS, a non-GAAP measure, is defined as the Company’s fully-diluted net income per share excluding non-cash acquisition-related intangible amortization, non-cash share-based compensation expense and certain board approved non-recurring items on a tax-adjusted basis.
The Company’s management team and Board of Directors believe the use of Cash EPS as the measure for vesting terms is appropriate as it can be used to analyze the Company’s operating performance on a consistent basis by removing the impact of certain non-cash and non-recurring items from the Company’s operations, and by rewarding organic growth and accretive business transactions. However, as Cash EPS is a non-GAAP measure, it may not be the sole or best measure for investors to gauge the Company’s overall financial performance. The Audit Committee of the Company’s Board of Directors will be responsible for validating the calculation of Cash EPS growth over the relevant period.
In the aggregate, approximately 58% of the 3.6 million underlying shares of the Company’s common stock associated with the January 5, 2009 grants are subject to performance-based vesting criteria associated with Cash EPS growth. 100% of the performance-based SSARs, which comprise 38% of the 3.6 million underlying shares granted, will vest upon the achievement of a 25% compounded annual growth rate of Cash EPS for the three-year period ending December 31, 2011. None of the performance-based SSARs will vest unless the Company achieves the aforementioned 25% Cash EPS growth rate.
The shares of restricted stock subject to performance-based vesting criteria vest as follows:
  •   50% vesting based on achievement of a 15% compounded annual growth rate of Cash EPS for the three-year period ending December 31, 2011
 
  •   Pro rata vesting of between 50% and 100% based on achievement of a compounded annual growth rate of Cash EPS between 15% and 25% for the three-year period ending December 31, 2011
 
  •   100% vesting based on achievement of a 25% compounded annual growth rate of Cash EPS for the three-year period ending December 31, 2011
In addition to meeting the performance targets as discussed above, the grantees must be employed by the Company for a full four years through December 31, 2012 in order for the awards that are subject to performance-based vesting criteria to vest. The Company believes this additional one-year period beyond the three-year performance measurement period will help to retain key leaders and top-performing employees of the Company.
The remaining 42% of the 3.6 million underlying shares of the Company’s common stock associated with the January 5, 2009 grants are solely service-based and vest over a four-year period, of which the restricted stock grants vest 100% on December 31, 2012 and the SSARs vest 25% annually beginning on December 31, 2009.

 

 

January 5, 2009 — NEO Grant Details
                                 
    Restricted Stock   SSARS
NEO   Service   Performance   Service   Performance
John A. Bardis
Chairman, President and
Chief Executive Officer
     53,236       106,471       121,542       239,803  
Rand A. Ballard
Senior Executive Vice President,
Chief Operating Officer and Chief Customer Officer
     38,617       77,233       88,166       173,952  
L. Neil Hunn
Executive Vice President and
Chief Financial Officer
     27,651       55,302       63,130       124,555  
Jonathan H. Glenn
Executive Vice President and
Chief Legal and Administrative Officer
     7,066       13,958       15,910       25,997  
Scott E. Gressett
Senior Vice President and
Chief Accounting Officer
     7,066       13,958       15,910       25,997  

 

 

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
         
  MedAssets, Inc.
 		  
January 7, 2009  By:   /s/ L. Neil Hunn    
    Name:   L. Neil Hunn   
    Title:   Executive Vice President and
Chief Financial Officer 		  
 

 

-----END PRIVACY-ENHANCED MESSAGE-----